Obesity Drugs and Devices Both Driven by Rapid Growth

With the rise of prevalence in obesity, much attention is being given to emerging treatment options — whether drugs or devices.  Considerable commercial potential lies in treatment options that are less invasive device treatments than bypass surgery and obesity drug options represent sort of a "least invasive possible" option, although many obesity drugs have been stuck in the "awaiting approval" stage for some time due to concerns about safety.

Nonetheless, in even the short run, obesity drugs are driving more revenue than devices, with the expected lion's share of obesity drug revenues coming from combination drugs.

By 2019, drug's share of the total obesity treatment market will will have increased only moderately, the aggregate market will have increased by over fourfold.  See the segmentation of obesity drugs and devices, below:

 

Source: MedMarket Diligence, LLC; Report #S835.

 

Posted via email from medmarket's posterous

Published by

P. Driscoll

Patrick Driscoll founded MedMarket Diligence and has become a leading source of analysis and insight in medical technology markets. He previously co-founded Medtech Insight and was a principal at Medical Data International. He has 25 years of experience assessing current and potential markets for medical technologies.

Leave a Reply